Vivus Urges Shareholders To Re-elect Current Board - Quick Facts

(RTTNews) - Responding to First Manhattan Co.'s or FMC July 2, 2013 open letter to Vivus stockholders, Vivus Inc. (VVUS) said that its plan to unlock the full potential of Qsymia is successfully being guided by its highly qualified and experienced management team. Vivus urged its shareholders to re-elect the current Board.

Vivus noted that Qsymia does not need to be "re-launched" and in fact, Vivus is ahead of schedule on its retail strategy for Qsymia. Vivus said that it recently launched Qsymia in approximately 8,000 certified retail pharmacies and are executing additional strategies to support its ongoing rollout to customers.

"VIVUS's current Board and management team are successfully doing everything FMC is suggesting needs to be done - why let them turn back the clock and further delay the success of Qsymia? FMC promises to "re-launch" Qsymia (phentermine and topiramate extended-release) capsules CIV if their director nominees are elected," Vivus said.

Vivus noted that the current Board and management team have critical institutional knowledge of Qsymia. The current vivus Board and management team have successfully achieved significant milestones including FDA approval to modify the highly restrictive REMS for Qsymia.